# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $14...
RBC Capital analyst Shagun Singh maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from...
A sentiment of risk aversion looms over the markets during Wednesday’s trading session, triggering midday losses across the boa...
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Wednesday. Following the market ...
Abbott Laboratories surpasses expectations with Q1 sales hitting $9.96B, a 10.8% rise driven by robust performance in Medical D...
Abbott Laboratories (NYSE:ABT) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.9...